The goal of this activity is for the clinicians to enhance their knowledge and understanding of recent efficacy and safety data, and the clinical significance of these in the context of the emerging therapy landscape IgA nephropathy
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
AMA PRA Category 1 Credit™Up to 0.5 credits
MOC types
No MOC
FDA REMS
No
Qualifies for MIPS
No
Target Specialties
Pricing
$54 – $4,128 per course
typical $950 · based on 60 courses listed here
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Foot & Ankle Surgery
- Gastroenterology
- General Internal Medicine
- General Pediatrics
- Head & Neck Surgery
- Interventional Radiology
- Medical Oncology
- Nephrology
- Neurology
- Neuromuscular Medicine
- Nuclear Medicine
- Obstetrics & Gynecology
- Pediatric Radiology
- Physical Medicine & Rehabilitation
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Urological Oncology
- Vascular Neurology
- Vascular Surgery
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pediatrics
- Radiology
- Rehabilitation
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Case-based learning
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedNov 14, 2025
-
Last day to claim creditNov 14, 2027 1 year left
-
Medscape, LLC Filling the Gaps: New Data and Insights on Emerging Therapies for IgA Nephropathy
-
PRIME Education, Inc. (PRIME®) New and Emerging Therapies in IgA Nephropathy: Latest Data and Clinical Implications
-
National Kidney Foundation Immunology in Action: Exploring B-Cell Directed Therapies for IgA Nephropathy
-
PeerVoice, Siyemi Europe Limited PeerVoice – 2025 Congress Highlights from Houston, Texas: Translating C3G and IC-MPGN Trials To Treatment in an Era of Complement Inhibition
-
PeerVoice, Siyemi Europe Limited PeerVoice – Emerging CAR-T Strategies in gMG and SPS: What Are We Learning About Their Therapeutic Potential?
-
PeerVoice, Siyemi Europe Limited PeerVoice – Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention? Enduring
